세계의 분자진단 시장 : 산업 분석 - 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the global molecular diagnostics market. This report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, and offers detailed insights into the market structure.

Key Insights:

• Molecular Diagnostics Market Size (2024E): USD 23.2 Bn
• Projected Market Value (2031F): USD 35.6 Bn
• Global Market Growth Rate (CAGR 2024 to 2031):6.2%

Molecular Diagnostics Market - Report Scope:

Molecular diagnostics involve the analysis of biological markers in the genome and proteome to diagnose and monitor diseases. This market includes technologies like polymerase chain reaction (PCR), next-generation sequencing (NGS), and in situ hybridization. Molecular diagnostics are essential for diagnosing genetic disorders, infectious diseases, and certain cancers, and play a crucial role in personalized medicine by providing insights into patient-specific disease profiles.

Market Growth Drivers:

The global molecular diagnostics market is driven by several key factors, including the increasing prevalence of genetic disorders and infectious diseases, and the growing demand for personalized medicine. Advancements in molecular diagnostic technologies, such as the development of high-throughput sequencing and advanced bioinformatics tools, are enhancing diagnostic accuracy and efficiency. The rise in healthcare expenditures and the increasing focus on preventive healthcare further contribute to market growth. Additionally, the expansion of molecular diagnostics in emerging markets and the growing adoption of molecular tests in oncology are creating new opportunities for market expansion.

Market Restraints:

Despite promising growth prospects, the molecular diagnostics market faces challenges related to high costs and complex regulatory requirements. The high price of advanced diagnostic equipment and tests can limit access in low-resource settings and emerging economies. Additionally, the stringent regulatory processes for approval and reimbursement of molecular diagnostic tests can impede market entry and slow down innovation. The need for continuous investment in R&D and the necessity to comply with regulatory standards pose significant barriers to market growth.

Market Opportunities:

The molecular diagnostics market presents significant opportunities driven by technological advancements, demographic trends, and evolving healthcare needs. Innovations in molecular diagnostic technologies, such as the development of portable diagnostic devices and the integration of artificial intelligence (AI) in diagnostics, are opening new avenues for market growth. The increasing application of molecular diagnostics in various therapeutic areas, including oncology, infectious diseases, and genetic disorders, is expanding the market scope. Strategic partnerships, investments in R&D, and the introduction of cost-effective diagnostic solutions are essential for capitalizing on emerging opportunities and sustaining market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the molecular diagnostics market globally?
• Which diagnostic technologies and applications are driving the adoption of molecular diagnostics in different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the molecular diagnostics market?
• Who are the key players contributing to the molecular diagnostics market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global molecular diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global molecular diagnostics market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced diagnostic technologies, including next-generation sequencing and real-time PCR systems, catering to diverse diagnostic needs and clinical applications. Collaborations with healthcare providers, research institutions, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practices, and patient education fosters market growth and enhances diagnostic accuracy and outcomes.

Key Companies Profiled:

• Becton, Dickinson and Company
• Bio-Rad Laboratories In
• Merck KgaA
• Thermo Fisher Scientific Inc
• Agilent Technologies, Inc.
• F. Hoffman - La Roche Ltd.
• Illumina, Inc.
• Qiagen N.V.
• Hologic Inc.
• Siemens Healthineers AG
• Seegene, Inc.
• DiaSorin S.p.A
• Grifols, S.A.
• bioMerieux
• QuidelOrtho Corporation
• RapidBio

Molecular Diagnostics Market Research Segmentation

By Product Type:

• Instruments
• Reagent
• Assay Kits
• Consumables

By Disease Area:

• Infectious Disease
• Diabetes
• Cardiology
• Oncology
• Nephrology
• Autoimmune Disease
• Dermatology
• Wound Care
• Others

By End-use:

• Hospitals & Clinics
• Diagnostics Laboratories
• Academic and Research Institutes
• Biopharmaceutical Companies

By Region:

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Molecular Diagnostics Market Snapshot, 2024 - 2031
• 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Molecular Diagnostics Market: Value Chain
  • 2.3.1. List of Manufacturers
  • 2.3.2. List of Distributors
  • 2.3.3. Profitability Analysis
• 2.4. Macro-Economic Factors
  • 2.4.1. Global Sectorial Outlook
  • 2.4.2. Global GDP Growth Outlook
  • 2.4.3. Global Parent Market Overview
• 2.5. Forecast Factors - Relevance and Impact
• 2.6. Covid-19 Impact Assessment
• 2.7. Technology Advancement
• 2.8. Disease Epidemiology
• 2.9. Porter Five Force's Analysis
• 2.10. Regulatory Scenario
• 2.11. Product Adoption Analysis
• 2.12. Parent Market Analysis

3. Price Trend Analysis, 2024 - 2031

• 3.1. Key Highlights
• 3.2. Key Factors Impacting Product Prices
• 3.3. Prices by Product Type
• 3.4. Regional Prices and Product Preferences

4. Global Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 4.1. Key Highlights
  • 4.1.1. Market Volume (Units) Projections, by Product Type
  • 4.1.2. Market Size and Y-o-Y Growth
  • 4.1.3. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn ) Analysis and Forecast
  • 4.2.1. Historical Market Size Analysis, 2019-2023
  • 4.2.2. Current Market Size Forecast, 2024 - 2031
• 4.3. Global Molecular Diagnostics Market Outlook: Product Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis by Product Type, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 4.3.3.1. Instruments
      • 4.3.3.1.1. Polymerase Chain Reaction (PCR) Systems
      • 4.3.3.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 4.3.3.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 4.3.3.1.4. Microarrays
    • 4.3.3.2. Reagent
      • 4.3.3.2.1. Antibodies
      • 4.3.3.2.2. DNA Template
      • 4.3.3.2.3. DNA Polymerase
      • 4.3.3.2.4. Oligonucleotide Primers
      • 4.3.3.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 4.3.3.2.6. Buffer
    • 4.3.3.3. Assay Kits
    • 4.3.3.4. Consumables
• 4.4. Market Attractiveness Analysis: Product Type
• 4.5. Global Molecular Diagnostics Market Outlook: Disease Area
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn ) Analysis By Disease Area, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 4.5.3.1. Infectious Disease
    • 4.5.3.2. Diabetes
    • 4.5.3.3. Cardiology
    • 4.5.3.4. Oncology
    • 4.5.3.5. Nephrology
    • 4.5.3.6. Autoimmune Disease
    • 4.5.3.7. Dermatology
    • 4.5.3.8. Wound Care
    • 4.5.3.9. Others
• 4.6. Market Attractiveness Analysis: Disease Area
• 4.7. Global Molecular Diagnostics Market Outlook: End User
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn ) Analysis by End User, 2019-2023
  • 4.7.3. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 4.7.3.1. Hospitals & Clinics
    • 4.7.3.2. Diagnostics Laboratories
    • 4.7.3.3. Academic and Research Institutes
    • 4.7.3.4. Biopharmaceutical Companies
• 4.8. Market Attractiveness Analysis: End User

5. Global Molecular Diagnostics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn ) Analysis by Region, 2019-2023
• 5.3. Current Market Size (US$ Bn ) Forecast by Region, 2024 - 2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 6.2.1. by Country
  • 6.2.2. by Product Type
  • 6.2.3. By Disease Area
  • 6.2.4. by End User
• 6.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 6.4.1. Instruments
    • 6.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 6.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 6.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 6.4.1.4. Microarrays
  • 6.4.2. Reagent
    • 6.4.2.1. Antibodies
    • 6.4.2.2. DNA Template
    • 6.4.2.3. DNA Polymerase
    • 6.4.2.4. Oligonucleotide Primers
    • 6.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 6.4.2.6. Buffer
  • 6.4.3. Assay Kits
  • 6.4.4. Consumables
• 6.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 6.5.1. Infectious Disease
  • 6.5.2. Diabetes
  • 6.5.3. Cardiology
  • 6.5.4. Oncology
  • 6.5.5. Nephrology
  • 6.5.6. Autoimmune Disease
  • 6.5.7. Dermatology
  • 6.5.8. Wound Care
  • 6.5.9. Others
• 6.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 6.6.1. Hospitals & Clinics
  • 6.6.2. Diagnostics Laboratories
  • 6.6.3. Academic and Research Institutes
  • 6.6.4. Biopharmaceutical Companies
• 6.7. Market Attractiveness Analysis

7. Europe Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 7.2.1. by Country
  • 7.2.2. by Product Type
  • 7.2.3. By Disease Area
  • 7.2.4. by End User
• 7.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkiye
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 7.4.1. Instruments
    • 7.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 7.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 7.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 7.4.1.4. Microarrays
  • 7.4.2. Reagent
    • 7.4.2.1. Antibodies
    • 7.4.2.2. DNA Template
    • 7.4.2.3. DNA Polymerase
    • 7.4.2.4. Oligonucleotide Primers
    • 7.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 7.4.2.6. Buffer
  • 7.4.3. Assay Kits
  • 7.4.4. Consumables
• 7.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 7.5.1. Infectious Disease
  • 7.5.2. Diabetes
  • 7.5.3. Cardiology
  • 7.5.4. Oncology
  • 7.5.5. Nephrology
  • 7.5.6. Autoimmune Disease
  • 7.5.7. Dermatology
  • 7.5.8. Wound Care
  • 7.5.9. Others
• 7.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 7.6.1. Hospitals & Clinics
  • 7.6.2. Diagnostics Laboratories
  • 7.6.3. Academic and Research Institutes
  • 7.6.4. Biopharmaceutical Companies
• 7.7. Market Attractiveness Analysis

8. East Asia Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 8.2.1. by Country
  • 8.2.2. by Product Type
  • 8.2.3. By Disease Area
  • 8.2.4. by End User
• 8.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 8.4.1. Instruments
    • 8.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 8.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 8.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 8.4.1.4. Microarrays
  • 8.4.2. Reagent
    • 8.4.2.1. Antibodies
    • 8.4.2.2. DNA Template
    • 8.4.2.3. DNA Polymerase
    • 8.4.2.4. Oligonucleotide Primers
    • 8.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 8.4.2.6. Buffer
  • 8.4.3. Assay Kits
  • 8.4.4. Consumables
• 8.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 8.5.1. Infectious Disease
  • 8.5.2. Diabetes
  • 8.5.3. Cardiology
  • 8.5.4. Oncology
  • 8.5.5. Nephrology
  • 8.5.6. Autoimmune Disease
  • 8.5.7. Dermatology
  • 8.5.8. Wound Care
  • 8.5.9. Others
• 8.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 8.6.1. Hospitals & Clinics
  • 8.6.2. Diagnostics Laboratories
  • 8.6.3. Academic and Research Institutes
  • 8.6.4. Biopharmaceutical Companies
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 9.2.1. by Country
  • 9.2.2. by Product Type
  • 9.2.3. By Disease Area
  • 9.2.4. by End User
• 9.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
• 9.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 9.4.1. Instruments
    • 9.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 9.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 9.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 9.4.1.4. Microarrays
  • 9.4.2. Reagent
    • 9.4.2.1. Antibodies
    • 9.4.2.2. DNA Template
    • 9.4.2.3. DNA Polymerase
    • 9.4.2.4. Oligonucleotide Primers
    • 9.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 9.4.2.6. Buffer
  • 9.4.3. Assay Kits
  • 9.4.4. Consumables
• 9.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 9.5.1. Infectious Disease
  • 9.5.2. Diabetes
  • 9.5.3. Cardiology
  • 9.5.4. Oncology
  • 9.5.5. Nephrology
  • 9.5.6. Autoimmune Disease
  • 9.5.7. Dermatology
  • 9.5.8. Wound Care
  • 9.5.9. Others
• 9.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 9.6.1. Hospitals & Clinics
  • 9.6.2. Diagnostics Laboratories
  • 9.6.3. Academic and Research Institutes
  • 9.6.4. Biopharmaceutical Companies
• 9.7. Market Attractiveness Analysis

10. Latin America Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 10.2.1. by Country
  • 10.2.2. by Product Type
  • 10.2.3. By Disease Area
  • 10.2.4. by End User
• 10.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 10.4.1. Instruments
    • 10.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 10.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 10.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 10.4.1.4. Microarrays
  • 10.4.2. Reagent
    • 10.4.2.1. Antibodies
    • 10.4.2.2. DNA Template
    • 10.4.2.3. DNA Polymerase
    • 10.4.2.4. Oligonucleotide Primers
    • 10.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 10.4.2.6. Buffer
  • 10.4.3. Assay Kits
  • 10.4.4. Consumables
• 10.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 10.5.1. Infectious Disease
  • 10.5.2. Diabetes
  • 10.5.3. Cardiology
  • 10.5.4. Oncology
  • 10.5.5. Nephrology
  • 10.5.6. Autoimmune Disease
  • 10.5.7. Dermatology
  • 10.5.8. Wound Care
  • 10.5.9. Others
• 10.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 10.6.1. Hospitals & Clinics
  • 10.6.2. Diagnostics Laboratories
  • 10.6.3. Academic and Research Institutes
  • 10.6.4. Biopharmaceutical Companies
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 11.2.1. by Country
  • 11.2.2. by Product Type
  • 11.2.3. By Disease Area
  • 11.2.4. by End User
• 11.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 11.4.1. Instruments
    • 11.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 11.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 11.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 11.4.1.4. Microarrays
  • 11.4.2. Reagent
    • 11.4.2.1. Antibodies
    • 11.4.2.2. DNA Template
    • 11.4.2.3. DNA Polymerase
    • 11.4.2.4. Oligonucleotide Primers
    • 11.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 11.4.2.6. Buffer
  • 11.4.3. Assay Kits
  • 11.4.4. Consumables
• 11.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 11.5.1. Infectious Disease
  • 11.5.2. Diabetes
  • 11.5.3. Cardiology
  • 11.5.4. Oncology
  • 11.5.5. Nephrology
  • 11.5.6. Autoimmune Disease
  • 11.5.7. Dermatology
  • 11.5.8. Wound Care
  • 11.5.9. Others
• 11.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 11.6.1. Hospitals & Clinics
  • 11.6.2. Diagnostics Laboratories
  • 11.6.3. Academic and Research Institutes
  • 11.6.4. Biopharmaceutical Companies
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Becton, Dickinson and Company
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Bio-Rad Laboratories Inc
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Thermo Fisher Scientific Inc.
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. Merck KGaA
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Agilent Technologies, Inc.
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. Hoffmann la roche
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. Qiagen N.V.
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. Illumina, Inc.
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. DiaSorin S.p.A
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Hologic Inc.
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. Siemens Healthineers AG
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. Seegene, Inc.
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Grifols, S.A.
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy
  • 12.3.14. bioMerieux
    • 12.3.14.1. Overview
    • 12.3.14.2. Segments and Products
    • 12.3.14.3. Key Financials
    • 12.3.14.4. Market Developments
    • 12.3.14.5. Market Strategy
  • 12.3.15. QuidelOrtho Corporation
    • 12.3.15.1. Overview
    • 12.3.15.2. Segments and Products
    • 12.3.15.3. Key Financials
    • 12.3.15.4. Market Developments
    • 12.3.15.5. Market Strategy
  • 12.3.16. RapidBio
    • 12.3.16.1. Overview
    • 12.3.16.2. Segments and Products
    • 12.3.16.3. Key Financials
    • 12.3.16.4. Market Developments
    • 12.3.16.5. Market Strategy
  • 12.3.17. Abbott Laboratories
    • 12.3.17.1. Overview
    • 12.3.17.2. Segments and Products
    • 12.3.17.3. Key Financials
    • 12.3.17.4. Market Developments
    • 12.3.17.5. Market Strategy
  • 12.3.18. Danaher Corporation
    • 12.3.18.1. Overview
    • 12.3.18.2. Segments and Products
    • 12.3.18.3. Key Financials
    • 12.3.18.4. Market Developments
    • 12.3.18.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations